Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

370
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
370
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

455
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
455
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

284
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
284
Additional Routes of Drug Administration01:18

Additional Routes of Drug Administration

3.1K
Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
3.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

376
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
376

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability of Levodopa Cyclops<sup>®</sup> Compared to INBRIJA<sup>®</sup> During an off Episode in Parkinson's Disease Patients.

Journal of aerosol medicine and pulmonary drug delivery·2026
Same author

An In Vitro-In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops.

Pharmaceutics·2025
Same author

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis.

Pharmaceutics·2025
Same author

Therapeutic effect of an inhaled levodopa dry powder formulation on off episodes in patients with Parkinson's disease.

Therapeutic advances in neurological disorders·2024
Same author

Electronic monitoring with a digital smart spacer to support personalized inhaler use education in patients with asthma: The randomized controlled OUTERSPACE trial.

Respiratory medicine·2023
Same author

Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice.

Pharmaceutics·2023

Related Experiment Video

Updated: Aug 31, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Dry powder inhalation, part 2: the present and future.

Anne Haaije de Boer1, Paul Hagedoorn1, Floris Grasmeijer1,2

  • 1Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.

Expert Opinion on Drug Delivery
|August 19, 2022
PubMed
Summary

Technological advancements in the 20th century enabled the creation of modern dry powder inhalers (DPIs). Future DPI designs require improved lung deposition, simpler handling, and reduced medication errors for better patient outcomes.

Keywords:
AdherenceMulti-dose reservoir DPIcapsule DPIcarbon foot printcompliancedry powder inhalerlactose

More Related Videos

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

972
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.8K

Related Experiment Videos

Last Updated: Aug 31, 2025

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

972
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.8K

Area of Science:

  • Respiratory medicine
  • Pharmaceutical technology
  • Biomedical engineering

Background:

  • Modern dry powder inhalers (DPIs) evolved from 20th-century technological progress, particularly post-1950.
  • The historical link between technological developments and DPI design remains underexplored in existing reviews.

Purpose of the Study:

  • To connect key 20th-century technological advancements with the development of effective, mass-producible DPIs.
  • To analyze the diversity of current DPIs (single, multiple-unit, multi-dose) and their impact on therapy efficacy and correct usage.

Main Methods:

  • Literature review focusing on technological advancements and DPI evolution.
  • Analysis of PubMed and Google search results for relevant studies.
  • Discussion of current DPI types, their benefits, and drawbacks.

Main Results:

  • Technological breakthroughs around 1950 were crucial for designing effective, affordable, and mass-produced DPIs.
  • Current DPI diversity presents challenges for correct use and therapeutic efficacy.
  • Existing DPIs often suffer from poor lung deposition and high rates of incorrect usage.

Conclusions:

  • Future DPI development must prioritize increased fine particle doses and intuitive inhaler handling.
  • Addressing incorrect inhaler use and improving patient adherence are critical for enhancing DPI therapy.
  • Simplifying DPI operation and minimizing the need for multiple inhalers are essential for future designs.